BBIO
BridgeBio Pharma, Inc.
BBIO has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over BBIO overall, supported by stronger fundamentals and stronger modeled upside.
BBIO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Unavailable |
BBIO's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
BBIO PE Valuation
BBIO has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
BBIO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect BBIO's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
BBIO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.04 | +$1.17 |
| Q2 2026 | -$3.57 | +$0.55 |
| Q1 2026 | -$3.74 | -$0.18 |
| Q4 2025 | -$3.78 | -$0.90 |
| Q3 2025 | -$4.21 | -$1.79 |
| Q2 2025 | -$4.12 | -$1.48 |
| Q1 2025 | -$3.56 | -$0.33 |
| Q4 2024 | -$2.88 | +$1.07 |
BBIO is still losing money, but less than at its worst: $3.04 per share over the past year, against $4.21 at its worst in late 2025.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over BBIO on earnings quality, reporting a profit while its opponent remains loss making.
BBIO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $353.2M | +193% |
| Q2 2026 | $243.7M | +120% |
| Q1 2026 | $194.5M | +67% |
| Q4 2025 | $154.2M | +2521% |
| Q3 2025 | $120.7M | +4318% |
| Q2 2025 | $110.6M | +5000% |
| Q1 2025 | $116.6M | -45% |
| Q4 2024 | $5.9M | +237% |
BBIO's revenue has grown year over year for six quarters in a row: $353M last quarter, up 193% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -3.3% | +117 points |
| Q2 2026 | -44% | +78 points |
| Q1 2026 | -54% | +35 points |
| Q4 2025 | -91% | +3752 points |
| Q3 2025 | -120% | +6898 points |
| Q2 2025 | -121% | +7975 points |
| Q1 2025 | -89% | -90 points |
| Q4 2024 | -3843% | +6324 points |
BBIO's operating margin was −3.3% last quarter, up 117 points from the same quarter a year ago, near the top of its range since 2019.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR's revenue has grown year over year every quarter since early 2021: $5.1B last quarter, up 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over BBIO on profitability, with a higher operating margin.
BBIO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$44.5M | +$65.6M |
| Q2 2026 | -$71.5M | +$9.7M |
| Q1 2026 | -$197.3M | +$1.9M |
| Q4 2025 | -$56.5M | +$138.9M |
| Q3 2025 | -$110M | +$70.7M |
| Q2 2025 | -$81.3M | -209% |
| Q1 2025 | -$199.2M | +$21M |
| Q4 2024 | -$195.4M | -$70.1M |
BBIO has burned cash in almost every quarter: −$370M over the past year, against −$586M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over BBIO on cash generation, producing positive trailing cash flow while its opponent burns cash.
BBIO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +244K shares |
| 1 year | +2.2% | +4.2M shares |
| 3 years | +20% | +32.7M shares |
| 5 years | +34% | +49.4M shares |
| Available history | +87% | +90.9M shares |
BBIO has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $42.5M |
| Q2 2026 | $127.5M |
| Q1 2026 | $82.5M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $48.3M |
| Q4 2021 | $1.5M |
BBIO spent $253M buying back its own shares over the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
BBIO Net Leverage
BBIO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
BBIO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.4 | Neutral |
| Stochastic | 48.6 | Neutral |
BBIO's weekly RSI is 57 (neutral) and its Stochastic is 49 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
BBIO PE vs Healthcare Sector
BBIO has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
BBIO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $70.1 | 12% above |
| 20 week MA | $75.3 | 3.9% above |
| 50 week MA | $73.0 | 7.1% above |
| 100 week MA | $58.0 | 35% above |
| 200 week MA | $41.6 | 88% above |
BBIO is in an uptrend: it's above all five of its weekly moving averages, and 88% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
BBIO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $36.8 | $69.5 | +89% |
| 2021 | $69.5 | $40.6 | -42% |
| 2022 | $40.6 | $7.88 | -81% |
| 2023 | $7.88 | $40.4 | +412% |
| 2024 | $40.4 | $28.0 | -31% |
| 2025 | $28.0 | $75.8 | +171% |
| 2026 YTD | $75.8 | $78.2 | +3.1% |
BBIO's yearly returns have swung widely, from +412% in 2023 to −81% in 2022. It's up 3.1% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over BBIO on returns for 2026, with the stronger performance.